SITC - Crisis in Clinical Research Virtual Summit


August 17, 2022

Virtual |

Since 2011, the approval of more than 100 immuno-oncology(I-O) products have radically changed the cancer treatment landscape and the clinical trial pipeline. Rapid development of promising I-O therapies represents the greatest opportunity for cancer patients, but future progress is severely threatened by persistent challenges in clinical research. 

The Society for Immunotherapy of Cancer (SITC) convened thought leaders from the National Cancer Institute (NCI), the Food and Drug Administration (FDA), biopharmaceutical companies, contract research organizations, and other major oncology professional organizations to address these challenges through meaningful discussion at a virtual summit that was appropriately titled Crisis in Clinical Research.  

Chris Learn.pngParexel's own Chris Learn, Vice President of Cell and Gene Therapy, CoE had the privilege of joining this distinguished group of thought leaders and participating in a panel discussion on how we can reduce burden of scientific review.The discussion was thought-provoking and worth sharing. Parexel is boldly taking action to drive our industry forward so we can all bring the best science to market, as quickly as possible, to make a difference for patients.

This session has already passed, but you can listen to the recording  on "Reducing the Burden of Scientific Review and Maximizing Efficiency in Meeting Regulartory Requirements at your leisure.


We are always available for a conversation.


We are always available for a conversation.


Communication Preference

Communication Preference